GSK’s Ziagen Relabeled: REMS And The Path To Personalized Medicine
Executive Summary
A relabeling of GlaxoSmithKline's HIV treatment Ziagen (abacavir sulfate) to recommend pharmacogenomic screening illustrates the potential for FDA's new drug safety tools to encourage the push towards personalized medicine